tricuspid

ACC 2023 | TRILUMINATE Pivotal: Edge-to-Edge Treatment in Patients with Tricuspid Regurgitation

Tricuspid regurgitation is a common and impairing disease. Optimal medical therapy (OMT) is limited, valve surgery is complex, and mortality is not low. Dr. Paul Sorajja presented the results of the Pivotal Triluminate study to demonstrate the safety and efficacy of edge-to-edge treatment (transcatheter edge-to-edge repair, TEER) in tricuspid regurgitation. Three hundred and fifty patients<a href="https://solaci.org/en/2023/03/08/acc-2023-triluminate-pivotal-edge-to-edge-treatment-in-patients-with-tricuspid-regurgitation/" title="Read more" >...</a>

Válvula Tricúspide: nuevas opciones de tratamiento estructural percutáneo

Watch Again Tricuspid Valve: New Options for Structural Percutaneous Treatment

Enjoy once again a new SOLACI Sessions event: “Tricuspid Valve: New Options for Structural Percutaneous Treatment” on our YouTube channel. The event, sponsored by P&amp;F, was attended by renowned opinion leaders in the region and featured important dissertations and case study discussions. Watch it here below! Tricuspid Valve: New Options for Structural Percutaneous Treatment

La insuficiencia renal post tratamiento borde a borde tricuspídeo impacta en el pronóstico

Prognostic Impact of Acute Kidney Injury Following Tricuspid Transcatheter Edge-to-Edge Repair

Tricuspid failure (TF) mostly affects the elderly and, because of this, is associated with comorbidities that increase surgical risk.&nbsp; Tricuspid edge to edge repair (TEER) has surged as a valid alternative for the mitral valve in high-risk patients and, at present, is increasingly being used for tricuspids.&nbsp; One of the complications following TEER is acute<a href="https://solaci.org/en/2022/10/12/prognostic-impact-of-acute-kidney-injury-following-tricuspid-transcatheter-edge-to-edge-repair/" title="Read more" >...</a>

ATC sobre arterias nativas o puentes venosos, ¿cuál tiene mejor pronóstico?

Tricuspid Regurgitation: Edge-to-Edge Treatment with PASCAL

About 4% of the population suffers from tricuspid regurgitation (TR). This disease is associated with hard-to-manage heart failure (HF)—often requiring hospitalization—and with mortality. Surgery in this valve is not simple and has high morbidity and mortality rates due to its comorbidities. Currently, a percutaneous strategy for its resolution is under development, but we still do<a href="https://solaci.org/en/2022/07/21/tricuspid-regurgitation-edge-to-edge-treatment-with-pascal/" title="Read more" >...</a>

TRICVALVE en pacientes con Insuficiencia tricuspídea severa: resultados alentadores a 6 meses

TRICVALVE in Patients with Severe Tricuspid Regurgitation: Promising Results at 6 months

Severe tricuspid regurgitation (TR) is associated with high mortality and morbidity. For patients with high surgical risk that cannot get surgery, the endovascular option has become an attractive solution this past decade.&nbsp; Transcatheter intervention has focused on edge-to-edge repair and valve replacement. However, their success depends on anatomical characteristics and imaging guidance effectiveness.&nbsp; The bicaval<a href="https://solaci.org/en/2022/07/15/tricvalve-in-patients-with-severe-tricuspid-regurgitation-promising-results-at-6-months/" title="Read more" >...</a>

EuroPCR 2022

EuroPCR 2022 | CLASP TR Study: Promising Results of Endovascular Intervention of Tricuspid Regurgitation

At present, we are well aware of the rise in mortality caused by severe tricuspid regurgitation (TR). Medical and surgical treatments have turned out to be suboptimal. Hence, endovascular intervention presents as an alternative therapeutic strategy with promising results.&nbsp; The aim of this multicenter, prospective study was to assess the safety and efficacy of the<a href="https://solaci.org/en/2022/05/30/europcr-2022-clasp-tr-study-promising-results-of-endovascular-intervention-of-tricuspid-regurgitation/" title="Read more" >...</a>

EuroPCR 2022 | Cambios en el daño cardíaco luego del reemplazo valvular aórtico por cirugía

EuroPCR 2022 | Real World Outcomes on Edge-to-Edge Tricuspid Valve Repair: 30 Day Outcomes of the TriClip bRight

This study was carried out to assess the safety and efficacy of the TriClip (edge-to-edge repair) in patients with severe tricuspid regurgitation with persistent symptoms despite medical treatment and high surgical risk.&nbsp; It is a prospective multicenter single arm study including 300 patients of mean age 78±7.6; 7.7% presented prior aortic intervention and 28% prior<a href="https://solaci.org/en/2022/05/26/europcr-2022-real-world-outcomes-on-edge-to-edge-tricuspid-valve-repair-30-day-outcomes-of-the-triclip-bright/" title="Read more" >...</a>

EuroPCR 2022 | Cambios en el daño cardíaco luego del reemplazo valvular aórtico por cirugía

EuroPCR 2022 | 1 Year Outcomes of Tricuspid Valve Repair with Cardioband: Feasibility Study

Tricuspid failure is a prevalent valvulopathy most often mistreated. It has been associated with high surgical risk and medical treatment has showed substandard therapeutic effect. Surgical repair with valve annuloplasty is the technique of choice for its long-term durability. Transcatheter repair of the tricuspid valve is an alternative that aims at imitating annuloplasty by reducing<a href="https://solaci.org/en/2022/05/24/europcr-2022-1-year-outcomes-of-tricuspid-valve-repair-with-cardioband-feasibility-study/" title="Read more" >...</a>

ACC 2022

ACC 2022 | CLASP TR Study: Tricuspid Valve Repair with the PASCAL Device

The study included 65 patients who received endovascular treatment of the tricuspid valve with the PASCAL device. Forty-six completed the 12-month follow-up. At 1-year follow-up, the major events endpoint was 16.9%; the most frequent event was bleeding (9.2%). In addition, there were three cases of stroke, one reintervention, two vascular access complications, and five cardiovascular-related<a href="https://solaci.org/en/2022/04/13/acc-2022-clasp-tr-study-tricuspid-valve-repair-with-the-pascal-device/" title="Read more" >...</a>

Top